At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
belinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of PXD101 in Patients With Unresectable Hepatocellular Carcinoma With Pharmacokinetic and Pharmacodynamic Evaluation
In Brief
A Phase 2 clinical trial evaluating belinostat for Adult Primary Hepatocellular Carcinoma and 3 related conditions. Completed, enrolled 54 participants across 2 sites in 2 countries.
Detailed Summary
This phase I/II trial is studying the side effects and best dose of belinostat and to see how well it works in treating patients with liver cancer that cannot be removed by surgery. Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
CountriesSingapore, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedMay 2006
Primary CompletionAug 2010
Study CompletionOct 2012
TodayJul 2026
First PostedMay 4, 2006
Enrollment StartMay 1, 2006
Primary CompletionAug 1, 2010
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 20.2 years ago
Interventions
belinostatdrug
Given IV